Literature DB >> 32330938

A multicentre study to optimize echinocandin susceptibility testing of Aspergillus species with the EUCAST methodology and a broth microdilution colorimetric method.

Joseph Meletiadis1,2, Maria Siopi1, Lamprini Kanioura2, Karin Meinike Jørgensen3, David S Perlin4, Johan W Mouton2, Maiken Cavling Arendrup3,5,6.   

Abstract

BACKGROUND: The determination of the minimal effective concentration (MEC) of echinocandins against Aspergillus species is subjective, time consuming and has been associated with very major errors.
METHODS: The MECs/MICs of 40 WT [10 each of Aspergillus fumigatus species complex (SC), Aspergillus flavus SC, Aspergillus terreus SC and Aspergillus niger SC] and 4 non-WT A. fumigatus isolates were determined with EUCAST E.Def 9.3.1 read microscopically, macroscopically, spectrophotometrically and colorimetrically in three centres. The optimal conditions for spectrophotometric (single- versus multi-point readings) and colorimetric (XTT/menadione concentration and stability, incubation time) methods were evaluated in preliminary studies using different cut-offs for the determination of macroscopic, spectrophotometric and colorimetric MIC endpoints compared with the microscopically determined MEC. Inter-centre and inter-method essential (within one 2-fold dilution) agreement (EA) and categorical agreement (CA) were determined.
RESULTS: Both macroscopic and spectrophotometric endpoint readings showed poor inter-centre EA (53%-66%) and low CA (41%-88%) in distinguishing WT from non-WT A. fumigatus SC isolates, while significant differences compared with the microscopic MECs were observed for all echinocandins (EA 6%-54%). For the colorimetric method, the optimal conditions were 400 mg/L XTT/6.25 μΜ menadione, incubation for 1-2 h until the drug-free control reached an absorbance at 450/630 nm of >0.8 and use of 50% inhibition of XTT conversion as a cut-off for all species and echinocandins. All non-WT isolates had high XTT MICs >1 mg/L, whereas the overall inter-centre EA and CA were 72%-89% and 100%, respectively.
CONCLUSIONS: The XTT colorimetric assay improved the antifungal susceptibility testing of echinocandins against Aspergillus spp., reliably detecting non-WT isolates.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32330938      PMCID: PMC7303820          DOI: 10.1093/jac/dkaa102

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  20 in total

1.  A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus.

Authors:  Eleusa Maria F Rocha; Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

2.  EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds.

Authors: 
Journal:  Clin Microbiol Infect       Date:  2008-10       Impact factor: 8.067

3.  Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species.

Authors:  Charalampos Antachopoulos; Joseph Meletiadis; Tin Sein; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

4.  Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], for antifungal susceptibility testing of Aspergillus species.

Authors:  J Meletiadis; J W Mouton; J F Meis; B A Bouman; P J Donnelly; P E Verweij
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

5.  Colorimetric assay for antifungal susceptibility testing of Aspergillus species.

Authors:  J Meletiadis; J W Mouton; J F Meis; B A Bouman; J P Donnelly; P E Verweij
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

6.  Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).

Authors:  A Espinel-Ingroff; A Fothergill; J Fuller; E Johnson; T Pelaez; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

7.  Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin.

Authors:  Adrienne Madureira; Anne Bergeron; Claire Lacroix; Marie Robin; Vanderson Rocha; Régis Peffault de Latour; Christèle Ferry; Agnès Devergie; Jordane Lapalu; Eliane Gluckmana; Gérard Socié; Mahmoud Ghannoum; Patricia Ribaud
Journal:  Int J Antimicrob Agents       Date:  2007-12       Impact factor: 5.283

8.  Nonsporulating clinical isolate identified as Petromyces alliaceus (anamorph Aspergillus alliaceus) by morphological and sequence-based methods.

Authors:  S Arunmozhi Balajee; Mark D Lindsley; Naureen Iqbal; James Ito; Peter G Pappas; Mary E Brandt
Journal:  J Clin Microbiol       Date:  2007-05-30       Impact factor: 5.948

9.  Mould breakthrough in immunosuppressed adults receiving anidulafungin: a report of 2 cases.

Authors:  Gene A Wetzstein; Myke R Green; John N Greene
Journal:  J Infect       Date:  2007-09-27       Impact factor: 6.072

10.  Caspofungin-resistant Aspergillus flavus after heart transplantation and mechanical circulatory support: a case report.

Authors:  S Eschertzhuber; C Velik-Salchner; C Hoermann; D Hoefer; C Lass-Florl
Journal:  Transpl Infect Dis       Date:  2007-07-01       Impact factor: 2.228

View more
  6 in total

Review 1.  Aspergillus fumigatus and aspergillosis: From basics to clinics.

Authors:  A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl
Journal:  Stud Mycol       Date:  2021-05-10       Impact factor: 16.097

2.  Comparative Pharmacodynamics of Echinocandins against Aspergillus fumigatus Using an In Vitro Pharmacokinetic/Pharmacodynamic Model That Correlates with Clinical Response to Caspofungin Therapy: Is There a Place for Dose Optimization?

Authors:  Maria Siopi; David S Perlin; Maiken C Arendrup; Spyros Pournaras; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

3.  Amphotericin B and Curcumin Co-Loaded Porous Microparticles as a Sustained Release System against Candida albicans.

Authors:  Baiji Xue; Yanhua Yu; Guoqiang Peng; Mengmeng Sun; Peng Lv; Xuefeng Li
Journal:  Molecules       Date:  2022-05-11       Impact factor: 4.927

4.  In Vitro Activity of Manogepix (APX001A) and Comparators against Contemporary Molds: MEC Comparison and Preliminary Experience with Colorimetric MIC Determination.

Authors:  Karin Meinike Jørgensen; Karen M T Astvad; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

5.  Echinocandins and Their Activity against Aspergillus terreus Species Complex: a Novel Agar Screening Method.

Authors:  Nina Lackner; Roya Vahedi-Shahandashti; Sonja Jähnig; Lea Schönherr; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2021-12-13       Impact factor: 5.938

6.  Invasive Trichoderma spp. infections: clinical presentation and outcome of cases from the literature and the FungiScope® registry.

Authors:  Ertan Sal; Jannik Stemler; Jon Salmanton-García; Iker Falces-Romero; László Kredics; Elisabeth Meyer; Benjamin Würstl; Cornelia Lass-Flörl; Zdenek Racil; Nikolay Klimko; Simone Cesaro; Anupma Jyoti Kindo; Hilmar Wisplinghoff; Philipp Koehler; Oliver A Cornely; Danila Seidel
Journal:  J Antimicrob Chemother       Date:  2022-09-30       Impact factor: 5.758

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.